The secondary analysis of the SOUL trial from JAMA Internal Medicine 2026 proves for the first time: Oral semaglutide significantly reduces heart failure events in patients with pre-existing HFpEF – without safety signals, even with concomitant SGLT2 inhibitor therapy. Heart failure is one of the most common and prognostically most serious complications of type 2 diabetes. GLP-1 receptor agonists in subcutaneous formulation have already been shown to be effective in reducing heart failure events. With the secondary analysis of the SOUL trial, comprehensive data is now available for the first time for the oral formulation of semaglutide – and it shows: Heart failure outcomes are improved primarily in patients with preserved ejection fraction (HFpEF), while no effect is detectable in patients with reduced EF (HFrEF). A finding with immediate clinical relevance.
Jetzt beitreten
